Neurogene Inc. Finance Lease, Interest Payment on Liability
Neurogene Inc. (NGNE) reported Finance Lease, Interest Payment on Liability of $70.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FinanceLeaseInterestPaymentOnLiability · last filed 2026-03-24
- Neurogene Inc. finance lease, interest payment on liability for the quarter ending 2024-12-31 was $19.00K.
- Neurogene Inc. finance lease, interest payment on liability for the quarter ending 2024-09-30 was $12.00K.
- Neurogene Inc. finance lease, interest payment on liability for the quarter ending 2024-06-30 was $20.00K.
- Neurogene Inc. finance lease, interest payment on liability for the quarter ending 2024-03-31 was $13.00K.
- Neurogene Inc. finance lease, interest payment on liability for fiscal 2025 was $70.00K, a 9.38% increase from fiscal 2024.
- Neurogene Inc. finance lease, interest payment on liability for fiscal 2024 was $64.00K, a 52.38% increase from fiscal 2023.
- Neurogene Inc. finance lease, interest payment on liability for fiscal 2023 was $42.00K, a 1300.00% increase from fiscal 2022.
- Neurogene Inc. finance lease, interest payment on liability for fiscal 2022 was $3.00K.
| Period end | Finance Lease, Interest Payment on Liability 3 month | Finance Lease, Interest Payment on Liability 6 month | Finance Lease, Interest Payment on Liability 9 month | Finance Lease, Interest Payment on Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $70.00K 10-K · filed 2026-03-24 | |||
| 2024-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $31.00K derived: sum of 2 quarters · filed 2026-03-24 | $51.00K derived: sum of 3 quarters · filed 2026-03-24 | $64.00K 10-K · filed 2026-03-24 |
| 2024-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $32.00K derived: sum of 2 quarters · filed 2024-11-18 | $45.00K 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $33.00K 10-Q · filed 2024-08-09 | ||
| 2024-03-31 | $13.00K 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | $42.00K 10-K · filed 2025-03-24 | |||
| 2022-12-31 | $3.00K 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |